DK3156485T3 - Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter - Google Patents
Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter Download PDFInfo
- Publication number
- DK3156485T3 DK3156485T3 DK16196481.2T DK16196481T DK3156485T3 DK 3156485 T3 DK3156485 T3 DK 3156485T3 DK 16196481 T DK16196481 T DK 16196481T DK 3156485 T3 DK3156485 T3 DK 3156485T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- cells
- antibody
- sequence
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. Fremgangsmåde til udvikling af et protein i en eukaryotisk celleproduktionsvært, hvilken fremgangsmåde omfatter: a. udvikling af et modelprotein til at producere et sæt mutante proteiner i den eukaryotiske celleproduktionsvært; b. screening af sættet af mutante proteiner efter i det mindste én forudbestemt egenskab, karakteristik eller aktivitet; c. udvælgelse af et opmuteret protein blandt sættet af mutante proteiner baseret på den i det mindste ene forudbestemte egenskab, karakteristik eller aktivitet; og d. fremstilling af det opmuterede protein, omfattende eksprimering af det opmu-terede protein i den samme eukaryotiske celleproduktionsvært som anvendt i udviklingstrinnet a.
2. Fremgangsmåde ifølge krav 1, hvor udvælgelsestrinnet (c) omfatter: udvælgelse af det opmuterede protein fra sættet af mutante proteiner baseret på i. optimering af den i det mindste ene forudbestemte egenskab, karakteristik eller aktivitet valgt blandt reduktion af protein-proteinaggregation, forbedring af proteinstabilitet, forøgelse af proteinopløselighed, indføring af glycosyleringspositioner, indføring af konjugeringspositioner, forbedring af proteinekspression, forøget antigenaffinitet, en ændring i bindingsaffinitet, en ændring i immunogenisitet, en forøget selektivitet og en forøgelse af specificitet, i sammenligning med modelproteinet; og ii. modificeret ekspression i sammenligning med modelproteinet.
3. Fremgangsmåde ifølge krav 1, hvor udvælgelsestrinnet (c) omfatter: udvælgelse af det opmuterede protein fra sættet af muterede proteiner baseret på i. optimering af den i det mindste ene forudbestemte egenskab, karakteristik eller aktivitet valgt blandt en forøget protein pH-stabilitet, en forøget temperaturstabilitet, en forøget proteinopløsningsmiddelstabilitet, en formindsket selektivitet, en formindsket antigenaffinitet, en ændring i katalytisk aktivitet, pH optimering, og en reduktion af immunogenisitet; og ii. modificeret ekspression i sammenligning med modelproteinet.
4. Fremgangsmåde ifølge ethvert af kravene 2-3, hvor den modificerede ekspression er forbedret ekspression i den eukaryotiske celleproduktionsvært.
5. Fremgangsmåde ifølge krav 1, hvor udviklingstrinnet a. omfatter en af omfattende positionsmæssig evolution; omfattende positionsmæssig indsætningsevolution; omfattende positionsmæssig deletionsevolution; omfattende positionsmæssig evolution efterfulgt af kombinatorisk proteinsyntese; omfattende positionsmæssig deletionsevolution efterfulgt af kombinatorisk proteinsyntese; eller omfattende positionsmæssig deletionsevolution efterfulgt af kombinatorisk proteinsyntese.
6. Fremgangsmåde ifølge krav 1, hvor modelproteinet er valgt blandt et enzym, et cyto-kin, en receptor, et DNA-bindende protein, et chelateringsmiddel, et antistof og et hormon.
7. Fremgangsmåde ifølge krav 1, hvor modelproteinet er et enzym, et cytokin eller en receptor.
8. Fremgangsmåde ifølge krav 1, hvor udviklingstrinnet a. omfatter udvikling af modelproteinet for fremstilling af et sæt af mutante proteiner i den eukaryotiske celleproduktionsvært med celleoverfladefremvisning.
9. Fremgangsmåde ifølge krav 1, hvor proteinet er et terapeutisk lægemiddel og det opmuterede protein er en biosimilar.
10. Fremgangsmåde ifølge krav 1, hvor ét eller flere stillemutationscodoner i proteinet udvælges og udvikles.
11. Fremgangsmåde ifølge krav 1, som yderligere omfatter trinnene med: generering af et proteinbibliotek i en eukaryotisk celleproduktionsvært; screening af biblioteket efter i det mindste én forudbestemt egenskab, karakteristik eller aktivitet; og udvælgelse af modelproteinet fra biblioteket baseret på den i det mindste ene forudbestemte egenskab, karakteristik eller aktivitet.
12. Fremgangsmåde ifølge krav 10, hvor genereringstrinnet omfatter generering af én af: i. n-1 separate sæt af muterede proteiner ved mutering af hver rest fra 2 til n af udgangsproteinet én ad gangen, idet hvert muteret protein har n aminosyrerester, hvert sæt af muterede proteiner omfatter muterede proteiner med et antal X af forskellige forudbestemte aminosyrerester ved en enkelt forudbestemt position fra 2 til n i det muterede protein; hvor hvert sæt af proteiner afviger fra udgangsproteinet alene i den enkelte forudbestemte position; og antallet af forskellige muterede proteiner, som er genereret, er ækvivalent med (n-1) x X, ii. n-1, eller n-2 i det tilfælde, hvor udgangsresten er methionin, separate muterede proteiner ved deletering hver rest fra 2 til n i udgangsproteinet, ét ad gangen, hvor hvert protein afviger fra udgangsproteinet ved, at én aminosyre er deleteret ved en enkelt forudbestemt position, og iii. 20 x (n-1) separate muterede proteiner ved indsætning af hver af de 20 naturligt forekommende aminosyrer i hver position imellem to tilstødende aminosyrerester i udgangsproteinet, ét ad gangen, hvor hvert muteret protein afviger fra udgangsproteinet ved, at det har indsat, efter en specifik position i udgangsproteinet, én af de 20 naturligt forekommende aminosyrer.
13. Fremgangsmåde ifølge krav 11, som yderligere omfatter trinnene med undersøgelse af hvert muteret protein efter i det mindste én forudbestemt egenskab, karakteristik eller aktivitet; for hvert muteret protein, identificering af en ændring i det nævnte egenskab, karakteristik eller aktivitet i forhold til en samme egenskab, karakteristik eller aktivitet for udgangsproteinet; dannelse af et funktionelt kort, som korrelerer hver mutation ved hver nævnt position i udgangsproteinet med den identificerede ændring i den nævnte egenskab, karakteristik eller aktivitet for hvert muteret protein i forhold til den samme egenskab, karakteristik eller aktivitet for udgangsproteinet; og anvendelse af det funktionelle kort for udviklingstrinnet.
14. Fremgangsmåde ifølge krav 1, hvor den eukaryotiske celleproduktionsvært er valgt blandt 3T3 musefibroblastceller; BHK21 syrisk hamsterfibroblastceller; MDCK, hunde-epitheliale celler, Hela humane epiteliale celler; PtK1 rottekænguruepiteliale celler; SP2/0 museplasmaceller; og NSO museplasmaceller, HEK 293 humane embryoniske nyreceller; COS abenyreceller; CHO; CHO-S kinesiske hamsterovarieceller; R1 museembryoniske celler, E14.1 museembryoniske celler; H1 humane embryoniske celler; H9 humane embryoniske celler; PER C.6, humane embryoniske celler; S. cerevisiae gærceller; og picchia gærceller.
15. Fremgangsmåde ifølge krav 1, hvor den eukaryotiske celleproduktionsvært er valgt blandt HEK 293 humane embryoniske nyreceller og CHO-S kinesiske hamsterovarieceller.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27116809P | 2009-07-17 | 2009-07-17 | |
| EP16157965.1A EP3042957B1 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3156485T3 true DK3156485T3 (da) | 2019-01-07 |
Family
ID=43450243
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19210622.7T DK3636759T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter |
| DK16196481.2T DK3156485T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter |
| DK18183032.4T DK3406717T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter |
| DK16157965.1T DK3042957T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af human protein-ydelse og ekspression i produktionsværter |
| DK15156820.1T DK2907873T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig integreret udvælgelse og udvikling af antistof-/protein-ydelse og deres eksprimering i produktionsværter |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19210622.7T DK3636759T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18183032.4T DK3406717T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter |
| DK16157965.1T DK3042957T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig, integreret udvælgelse og udvikling af human protein-ydelse og ekspression i produktionsværter |
| DK15156820.1T DK2907873T3 (da) | 2009-07-17 | 2010-07-16 | Samtidig integreret udvælgelse og udvikling af antistof-/protein-ydelse og deres eksprimering i produktionsværter |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8859467B2 (da) |
| EP (6) | EP3636759B1 (da) |
| JP (3) | JP6193570B2 (da) |
| KR (5) | KR20190017070A (da) |
| CN (2) | CN102625848A (da) |
| AU (5) | AU2010273974B2 (da) |
| BR (2) | BR112012001171B1 (da) |
| CA (2) | CA3034484A1 (da) |
| DK (5) | DK3636759T3 (da) |
| ES (3) | ES2701931T3 (da) |
| HK (1) | HK1210623A1 (da) |
| HU (1) | HUE029328T2 (da) |
| IN (1) | IN2012DN00737A (da) |
| MX (2) | MX347654B (da) |
| MY (2) | MY160472A (da) |
| PL (2) | PL3042957T3 (da) |
| PT (1) | PT3042957T (da) |
| SG (3) | SG177687A1 (da) |
| WO (1) | WO2011009058A2 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3636759B1 (en) | 2009-07-17 | 2023-10-11 | BioAtla, Inc. | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| EP2593797B1 (en) | 2010-07-16 | 2019-05-08 | Bioatla, LLC | Novel methods of protein evolution |
| AU2015242961B2 (en) * | 2010-07-16 | 2017-03-02 | Bioatla, Llc | Novel methods of protein evolution |
| JP6121904B2 (ja) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
| US20140302999A1 (en) * | 2011-11-03 | 2014-10-09 | Magdalena Leszczyniecka | Method for determination of pharmacological properties of recombinant proteins |
| US10156574B2 (en) | 2013-04-29 | 2018-12-18 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015105888A1 (en) * | 2014-01-07 | 2015-07-16 | Bioatla, Llc | Proteins targeting orthologs |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CA2947605A1 (en) * | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| CA2954066A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| RU2764074C2 (ru) * | 2014-08-28 | 2022-01-13 | Байоатла, Ллк | Условно активные химерные антигенные рецепторы для модифицированных т-клеток |
| US10513699B2 (en) | 2014-09-03 | 2019-12-24 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| CA2977687C (en) | 2015-02-24 | 2024-02-13 | Hwai Wen Chang | Conditionally active proteins |
| TWI748962B (zh) * | 2015-09-23 | 2021-12-11 | 美商建南德克公司 | 抗ｖｅｇｆ抗體之最佳化變異體 |
| US11472876B2 (en) | 2015-11-02 | 2022-10-18 | Bioatla, Inc. | Conditionally active polypeptides |
| SI3455261T1 (sl) | 2016-05-13 | 2023-01-31 | Bioatla, Inc. | Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh |
| PE20200757A1 (es) | 2017-07-11 | 2020-07-27 | Compass Therapeutics Llc | Anticuerpos agonistas que se unen a cd137 humano y sus usos |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN111048154B (zh) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | 一种抗体表位作图的方法 |
| CN111462815B (zh) * | 2020-03-27 | 2023-05-02 | 上海祥耀生物科技有限责任公司 | 一种抗体库的构建方法及装置 |
| US11506060B1 (en) * | 2021-07-15 | 2022-11-22 | Honeywell International Inc. | Radial turbine rotor for gas turbine engine |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
| EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| WO1989009284A1 (en) | 1988-03-24 | 1989-10-05 | University Of Iowa Research Foundation | Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| PT672145E (pt) | 1992-11-24 | 2003-08-29 | Searle & Co | Polipeptideos de interleucina-3(il-3) com multiplas mutacoes |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US8137906B2 (en) | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| US7033781B1 (en) | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| BR0207267A (pt) | 2001-02-19 | 2004-02-10 | Merck Patent Gmbh | Proteìnas artificiais com imunogenicidade reduzida |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| WO2002092780A2 (en) * | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| WO2005003345A2 (en) * | 2003-06-27 | 2005-01-13 | R. Crea & Co. | Look-through mutagenesis |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| EP1943332A4 (en) * | 2005-10-14 | 2011-04-13 | Medimmune Inc | CELLULAR DISPLAY OF ANTIBODY LIBRARIES |
| WO2008118476A2 (en) * | 2007-03-26 | 2008-10-02 | Codon Devices, Inc. | Cell surface display, screening and production of proteins of interest |
| US7947495B2 (en) | 2007-11-01 | 2011-05-24 | Abbott Biotherapeutics Corp. | Immunoglobulin display vectors |
| CA2704494A1 (en) | 2007-11-02 | 2009-05-14 | The Scripps Research Institute | Directed evolution using proteins comprising unnatural amino acids |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| EP3636759B1 (en) | 2009-07-17 | 2023-10-11 | BioAtla, Inc. | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2010
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 PT PT161579651T patent/PT3042957T/pt unknown
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/ko not_active IP Right Cessation
- 2010-07-16 ES ES16196481T patent/ES2701931T3/es active Active
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 MX MX2015005873A patent/MX347654B/es unknown
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/da active
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/es active Active
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/da active
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/es active Active
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en active Application Filing
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/da active
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/ko not_active Application Discontinuation
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/ko not_active Application Discontinuation
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/pt active IP Right Grant
- 2010-07-16 PL PL16157965T patent/PL3042957T3/pl unknown
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/ja active Active
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/pl unknown
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
- 2010-07-16 BR BR122015012748-3A patent/BR122015012748A2/pt not_active Application Discontinuation
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/zh active Pending
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/es active IP Right Grant
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/da active
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/zh active Pending
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/ko active Application Filing
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/da active
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/ko active IP Right Grant
-
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
-
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
-
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
-
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/ja active Active
- 2015-09-15 HK HK15109001.1A patent/HK1210623A1/zh unknown
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
-
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/ja active Active
-
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
-
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
-
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203220B2 (en) | Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts | |
| US11639365B2 (en) | Methods of protein evolution | |
| AU2020202783A1 (en) | Proteins targeting orthologs | |
| AU2017200658B2 (en) | Novel methods of protein evolution |